Trump Unveils Phased Tariff Timeline for Generic Drugs

Synopsis

President Donald Trump revealed that generic imports to the United States will continue to be duty-free for two years beginning Aug. 1, 2026, before duties will be raised to 100 percent and 200 percent in later years. The phased plan aims to incentivize pharma companies to invest in manufacturing plants in the United States, and has significant implications for global suppliers such as India's generics market.

Advertisement

The Announced Timeline

Effective Aug. 1, 2026, generic drugs entering the United States will retain a zero percent tariff rate for two years, then a 100 percent rate for one year and 200 percent rate thereafter, Trump said in a social media post. The policy was neither specific to any country or company, nor provided any detail on how the system would be administered.

The Reshoring Rationale

The escalating schedule was clear and obvious: The phased tariff system was designed to bring back generic drug manufacturing to the United States, including imposing a fine on companies that refuse to invest in manufacturing plants and equipment in the designated period, Trump said. The goal of the policy is to save the lives of Americans," he added.

Advertisement

How this fits the larger picture

This is not Washington's first tariff on pharmaceuticals. Under Section 232 of the Act the administration had already implemented a 100% tariff on patented pharmaceutical products and ingredients, at the time explicitly excluding generic drugs and biosimilars. The new announcement confirms that tariffs on patented, branded and innovative drugs will not change under Trump.

The stakes for global supply have been raised

Prescription drugs in the U.S. are dominated by generics. The Food and Drug Administration reports that over 90% of prescriptions are for generic medications in the U.S. This has a long term impact on the exporting countries, primarily India. The stakes are particularly high for India, which accounts for supplying almost 50% of all generic medicines consumed in the US.

Industry experts warn that two years could be too short a period. The shift highlights Trump's efforts to bring low-cost drug manufacturing back to the U.S., but it's a long process to establish a domestic pharmaceutical manufacturing base, said Deborah Elms, head of trade policy at the Hinrich Foundation.

Generics have thin margins and make up the majority of prescriptions in the United States, which means the tariffs on them will impact drug affordability more than the previous tariffs on higher-margin branded medicine.

Advertisement

Why It Matters

The two-year period provides a short runway for Indian pharmaceutical exporters such as Sun Pharma, Cipla and Dr. Reddy's, who provide a significant portion of the US generics market, to open up American manufacturing facilities or renegotiate supply deals in time for duties to kick in.

The long-term impact for American consumers depends on whether they can reshoring occur in time to mitigate the cost impact of eventual tariffs on medicines that many Americans use daily.